Drug Information

Drug General Information
Drug ID
D0W6AF
Former ID
DIB010175
Drug Name
YM-264
Drug Type
Small molecular drug
Indication Septic shock [ICD9: 785.52; ICD10:A41.9] Phase 2 [551827]
Company
Yamanouchi Pharmaceutical Co Ltd
Formula
C28H36N4O5S
Canonical SMILES
C1(NC(SC1)c1cnccc1)C(=O)N1CCN(CCC(c2ccccc2)(C)C)CC1.C(=<br />O)(/C=C/C(=O)O)O
CAS Number
CAS 131888-54-5
PubChem Compound ID
6439322
Target and Pathway
Target(s) Platelet-activating factor receptor Target Info Antagonist [530793]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Staphylococcus aureus infection
NetPath Pathway IL5 Signaling Pathway
Leptin Signaling Pathway
Reactome Class A/1 (Rhodopsin-like receptors)
G alpha (q) signalling events
Interferon gamma signaling
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Small Ligand GPCRs
Interferon gamma signaling
GPCR ligand binding
GPCR downstream signaling
References
Ref 551827Current Pharmaceutical Design. Page(175).
Ref 530793Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.